Skåne University Hospital is a university hospital in Scania, Sweden. The hospital was founded in 2010 through the merger of the two university hospitals in Lund and Malmö.

During the past decade, Skånes Universitetssjukhus conducted 87 clinical trials. In the 10-year time frame, 87 clinical trials started and 52 clinical trials were completed, i.e. on average, 59.8% percent of trials that started reached the finish line to date. In the past 5 years, 34 clinical trials started and 31 clinical trials were completed. i.e. 91.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Skånes Universitetssjukhus" #1 sponsor was "Janssen Research & Development, LLC" with 12 trials, followed by "Boehringer Ingelheim" with 10 trials sponsored, "Bayer" with 7 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored and "Pfizer" with 7 trials sponsored. Other sponsors include 99 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Skånes Universitetssjukhus" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "The Swedish Research Council" with 3 trials as a collaborator, "Uppsala University" with 3 trials as a collaborator, "AbbVie" with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator. Other collaborators include 50 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "Skånes Universitetssjukhus" are "Multiple Myeloma" (8 trials), "Atrial Fibrillation" (5 trials), "Chronic Lymphocytic Leukemia" (4 trials), "Prostate Cancer" (4 trials) and "Pulmonary Arterial Hypertension" (4 trials). Many other conditions were trialed in "Skånes Universitetssjukhus" in a lesser frequency.

Most popular intervention types in "Skånes Universitetssjukhus" are "Drug" (104 trials), "Other" (13 trials), "Biological" (11 trials), "Device" (10 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Rituximab" (5 trials), "Daratumumab" (4 trials), "Dexamethasone" (4 trials) and "Cyclophosphamide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Skånes Universitetssjukhus" are 135 trials for "All" genders, 8 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Skånes Universitetssjukhus". undefined are not yet recruiting, 28 are recruiting, 23 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 78 completed trials in Skånes Universitetssjukhus, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Skånes Universitetssjukhus, 8 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 71 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 17 trials that are defined as “Not Applicable".